16 Jul 2021 - Ad Hoc announcement pursuant to Art. 53 LR
Lonza Extends Collaboration with Major Biopharmaceutical Partner for Large-Scale Monoclonal Antibody Commercial Supply
Ad Hoc Release Pursuant to Art. 53 Listing Rules
- Long-term collaboration for commercial supply of monoclonal antibodies will complete the integrated supply chain for the manufacture of an antibody-drug conjugate (ADC) for use against hard-to-treat cancers
- The deal enables the customer to access commercial-scale production of all elements of its ADC at one site, ensuring security of supply and delivering significant economies of scale. It demonstrates the value of Lonza’s Ibex® Solutions, providing customers with fast, flexible and tailor-made solutions
- The monoclonal antibody manufacturing process will be delivered from Lonza’s recently announced large-scale facility currently under construction in Visp (CH)